Acumen Pharmaceuticals (ABOS) Equity Average (2020 - 2026)

Acumen Pharmaceuticals' Equity Average history runs 7 years deep, the most recent figure standing at $79.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 53.19% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $79.0 million (down 53.19% YoY), while the FY2025 annual figure was $126.1 million, down 43.79% from the prior year.
• Equity Average came in at $79.0 million for Q1 2026 at Acumen Pharmaceuticals, down from $81.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $273.6 million in Q4 2023 to a low of $79.0 million in Q1 2026.
• A 5-year average of $188.3 million and a median of $199.5 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 788.92% in 2022 and tumbled 59.0% in 2025, its largest moves.
• Acumen Pharmaceuticals' Equity Average stood at $192.7 million in 2022, then surged by 41.98% to $273.6 million in 2023, then slipped by 27.09% to $199.5 million in 2024, then sank by 59.0% to $81.8 million in 2025, then fell by 3.48% to $79.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $79.0 million, $81.8 million, and $105.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison